D.A. Davidson & Co’s United Therapeutics UTHR Stock Holding History

D.A. Davidson & Co’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-425	Closed	-$60K	–	2498
2016 Q4	$60K	Sell	425 -245	-37%	-$31.3K	﹤0.01%	1527
2016 Q3	$79K	Sell	670 -198	-23%	-$23.8K	﹤0.01%	1321
2016 Q2	$91K	Sell	868 -148	-15%	-$16.5K	﹤0.01%	1168
2016 Q1	$113K	Buy	+1,016	New	+$129K	﹤0.01%	1076
2015 Q1	–	Sell	-4,564	Closed	-$590K	–	2164
2014 Q4	$590K	Sell	4,564 -279	-6%	-$36K	0.02%	537
2014 Q3	$623K	Sell	4,843 -641	-12%	-$66.1K	0.02%	529
2014 Q2	$485K	Sell	5,484 -277	-5%	-$26.6K	0.02%	614
2014 Q1	$541K	Sell	5,761 -1,646	-22%	-$168K	0.02%	581
2013 Q4	$836K	Sell	7,407 -269	-4%	-$24.3K	0.03%	453
2013 Q3	$604K	Sell	7,676 -17	-0.2%	-$1.24K	0.03%	457
2013 Q2	$504K	Buy	+7,693	New	+$496K	0.02%	473

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.A. Davidson & Co's UTHR Position: Q1 2017 in Review

D.A. Davidson & Co sold out of United Therapeutics (UTHR) in Q1 2017, closing a stake of 425 shares — an estimated $60K sold.

D.A. Davidson & Co first reported a position in UTHR in Q2 2013 and held it in 11 quarters. The position peaked at $836K in Q4 2013. 411 funds tracked by Wall St. Rank hold UTHR as of Q1 2017.

D.A. Davidson & Co reported no remaining United Therapeutics position as of Q1 2017 after selling out during the quarter.
D.A. Davidson & Co sold 425 United Therapeutics shares in Q1 2017, an estimated $60K.
D.A. Davidson & Co first reported a position in United Therapeutics in Q2 2013 and held it in 11 quarters.
D.A. Davidson & Co's United Therapeutics position peaked at $836K in Q4 2013.
411 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2017.

Based on D.A. Davidson & Co's 13F filing for Q1 2017, filed 12 May 2017.